55150-443 : Regadenoson .08 mg/ml Intravenous Injection
NDC: | 55150-443 |
Labeler: | Eugia Us LLC |
Product Type: | Human Prescription Drug |
Drug Name: | Regadenoson |
Dosage Form: | Intravenous Injection |
Application #: | ANDA216437 |
Rev. Date: |
NDC Package Codes:
- 55150-443-01: 1 SYRINGE IN 1 CARTON (55150‑443‑01) > 5 ML IN 1 SYRINGE
Active Ingredients:
- Regadenoson
Dosage Strength:
- .08 mg/mL
Pharmaceutical Classes:
- Adenosine Receptor Agonists [MoA]
- Pharmacologic Cardiac Stress Test Agent [EPC]
Related Products:
Based on records with the same trade name.- 0409-1401 Regadenoson .08 mg/ml Intravenous Injection, Solution by Hospira, Inc.
- 0641-6253 Regadenoson .08 mg/ml Intravenous Injection, Solution by Hikma Pharmaceuticals USA Inc.
- 16729-477 Regadenoson .08 mg/ml Intravenous Injection, Solution by Accord Healthcare Inc.
- 36000-364 Regadenoson .08 mg/ml Intravenous Injection, Solution by Baxter Healthcare Corporation
- 43598-616 Regadenoson .08 mg/ml Intravenous Injection by Dr. Reddy's Laboratories Inc.
- 60505-6116 Regadenoson .08 mg/ml Intravenous Injection, Solution by Apotex Corp.
- 67457-994 Regadenoson .4 mg/5ml Intravenous Injection by Mylan Institutional LLC
- 68083-175 Regadenoson .08 mg/ml Intravenous Injection, Solution by Gland Pharma Limited
- 71288-201 Regadenoson .08 mg/ml Intravenous Injection, Solution by Meitheal Pharmaceuticals Inc.
- 72611-874 Regadenoson .08 mg/ml Intravenous Injection, Solution by Almaject, Inc.
- 76329-3321 Regadenoson .08 mg/ml Intravenous Injection, Solution by International Medication Systems, Limited
NDC QR Code
Scan the QR code below to easily reference this data in the future:< Prev: 55150-440Next: 55150-450 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.